People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Forty Seven, Inc. | — | Pharmaceuticals | Series C | $109.1M | $2.6B | 2017 |
Chris A. Schaepe at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chris A. Schaepe on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan MacQuitty | 1 | 7 |
| Christopher Schaepe | 1 | 6 |
| DENNIS HENNER | 1 | 5 |
| Jeffrey Bird | 1 | 5 |
| Eric Jensen | 1 | 5 |
| Irving Weissman | 1 | 2 |
| Mark A. McCamish | 1 | 2 |
| Jonathan A. MacQuitty | 1 | 1 |
| Ravindra A. Majeti | 1 | 1 |
| Irving A. Weissman | 1 | 1 |
| Dennis A. Henner | 1 | 1 |
| Jeffrey A. Bird | 1 | 1 |
| Ravindra Majeti | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.